NSE · Healthcare · Drug Manufacturers - Specialty & Generic
| Document | Date |
|---|---|
| Q1 FY27 earnings call WINDLAS BIOTECH LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Q1 FY27 revenue: INR 248 crores, up 18% Y-o-Y (highest ever quarterly revenue) • 14 con | 2026-08-14 |
| Quarterly results · Q1 FY27 WINDLAS BIOTECH LIMITED – Q1 FY27 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Revenue from operations: Rs 248 crores (Q1 FY27) vs Rs 210 crores (Q1 | 2026-08-10 |
| Investor presentation · Q1 FY27 WINDLAS BIOTECH LIMITED – Q1 FY27 INVESTOR SUMMARY --- HEADLINE NUMBERS • Revenue: Rs 248 Cr in Q1 FY27, up 18% YoY; highest quarterly revenue ever | 2026-08-10 |
| Annual report FY2026 WINDLAS BIOTECH LIMITED - FINANCIAL SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue from Operations: `9,040.89 millions (FY2025-26), up from | 2026-07-01 |
| Q4 FY26 earnings call WINDLAS BIOTECH LIMITED - Q4 & FY26 EARNINGS SUMMARY HEADLINE NUMBERS • FY26 revenue: INR 904 crores, up 19% YoY • Q4 FY26 revenue: INR 238 crores, | 2026-05-28 |
| Quarterly results · Q4 FY26 WINDLAS BIOTECH LIMITED – FY26 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Revenue from Operations (FY26): Rs 904 crores, up 19% YoY (FY25: Rs 760 | 2026-05-21 |
| Investor presentation · Q4 FY26 WINDLAS BIOTECH LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • Revenue FY26: Rs 904 Cr, up 19% YoY (Q4: Rs 238 Cr, up 18% YoY); 13th consecutive quar | 2026-05-21 |
| Q3 FY26 earnings call WINDLAS BIOTECH LIMITED – Q3 & 9M FY26 SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue: INR233 crores (20% Y-o-Y growth) • 9-Month FY26 Revenue: INR666 c | 2026-02-11 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹6.30 / share ex-date Jul 16, 2026 | 2026-07-16 |
| Announcement | Date |
|---|---|
| Closure of share buyback program effective May 16, 2026 Windlas Biotech Limited has informed the Exchange regarding Closure of Buy Back with effect from May 16, 2026 | 2026-05-18 |
| Post buyback public announcement newspaper publication Windlas Biotech Limited has published a post-buyback public announcement in newspapers as required by regulatory procedures. This is a formal disclosure notification to the stock exchange ab | 2026-05-16 |
| Letter of Offer submitted for share buyback program Windlas Biotech Limited has informed the Exchange about submission of Letter of Offer for Buyback | 2026-04-27 |
| Board resolution approved for share buyback public announcement in newspapers Windlas Biotech Limited has announced a share buyback program. The company formally notified the stock exchange about publishing official announcements regarding this buyback in newspapers, | 2026-04-20 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Windlas Biotech Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.